Analysis of Drug Use in a Patient with Rare Camrelizumab-induced Toxic Epidermal Necrolysis by Clinical Pharmacists
- VernacularTitle:临床药师对1例罕见卡瑞利珠单抗致中毒性表皮坏死松解症患者的用药分析
- Author:
Gongli HU
1
;
Jiawei LI
2
;
Yi XIAO
1
;
Yu HUANG
1
Author Information
1. Dept. of Pharmacy，Zigong Fourth People’s Hospital，Sichuan Zigong 643000，China
2. Dept. of Oncology，Zigong Fourth People’s Hospital，Sichuan Zigong 643000，China
- Publication Type:Journal Article
- Keywords:
Camrelizumab;
Toxic epidermal necrolysis;
ADR;
Pharmaceutical practice
- From:
China Pharmacy
2021;32(21):2672-2676
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To introduce the role of clinical pharmacists in the treatment of camrelizumab-induced toxic epidermal necrolysis （TEN），and to provide reference for the therapy of similar ADR. METHODS：The clinical pharmacist participated in therapy duration of a patient with TEN caused by camrelizumab. The patient was treated with Camrelizumab for injection combined with Apatinib mesylate tablet as anti-tumor therapy，and was admitted to hospital due to extensive skin lesions. After consulting relevant literatures and analyzing the patient’s admission diagnosis [severe epidermolysis bullosa，severe drug eruption（erythema multiforme），abnormal liver function，etc.] and examination results（hypokalemia，etc.），clinical pharmacists suggested to stop above anti-tumor drugs and given Methylprednisolone sodium succinate for injection（160 mg→80 mg→60 mg， qd，ivgtt） for anti-inflammatory treatment，Imiperan cilastatin for injection （1 g，q8 h，ivgtt） for an ti-infection treatment， Potassium chloride injection（1 g，qd，ivgtt）for electrolyte regulation，Compound amino acid injection（3AA）（10.65 g，qd，ivgtt） for nutritional support treatment，Pantoprazole sodium for injection（40 mg，qd，ivgtt）for acid inhibition and stomach protection， Reduced glutathione for injection（2.4 g，qd，ivgtt）for liver protection. Before medication，the patient was given cognitive and behavioral education and medication publicity. The changes of relevant indicators were closely monitored during medication，and the patient was given medication guidance when he was discharged. RESULTS：The doctors adopted the suggestions of clinical pharmacists，and 16 days after treatment，the skin lesions of the trunk and limbs were improved，and the double eyelids were still erosive and exuded a lot of secretions. The patient requested transfer for treatment. CONCLUSIONS：Clinical pharmacists assisted physicians to improve the treatment plan of patients with TEN caused by camrelizumab，and carried out cognitive and behavioral education and medication publicity for patients to ensure the effectiveness and safety of their medication.
